ROCO
6518
Market cap33mUSD
Oct 08, Last price
32.30TWD
1D
-1.82%
1Q
0.94%
Jan 2017
62.47%
IPO
-14.51%
Name
Concord Medical Co Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Concord Medical Co., Ltd. delivers extensive support services for hospital administration across Taiwan, Myanmar, and China. The company's portfolio of services includes critical medical management assistance, covering professional training for healthcare staff, the provision of nursing personnel, and general operational guidance. Additionally, Concord Medical offers comprehensive procurement solutions, sourcing a broad spectrum of items such as medical devices, pharmaceuticals, general medical supplies and consumables, as well as specialized inspection equipment and laboratory reagents. Expanding its ventures, the firm also develops and markets its own proprietary brands, which feature aesthetic healthcare products, nutritional supplements, and prepared traditional Chinese medicines. Furthermore, Concord Medical is actively involved in the strategic planning and sales of medical equipment, alongside offering medical apparatus leasing services. Concord Medical Co., Ltd. was established in 2009 and is headquartered in New Taipei City, Taiwan.
Key people
Vice Chairman of the Board · since 2022
Jiahong Lin
General Manager, Director · since 2023
Yangren Lai
Deputy General Manager · since 2015
Weiting Lu
Head of Finance · since 2025
Weilun Shi
Acting Head of Accounting · since 2025
Director · since 2021
Ching-Yi Liu
Chairman of the Board, Chief Executive Officer · since 2023
Zhechao Xu
Director · since 2009
Jiayu Jiang
Independent Director · since 2025
Yiyu Li
Independent Director · since 2022
Shuling Ye
Independent Director · since 2025
Valuation
Title TWD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||||
Revenues | |||||||
Cost of revenue | |||||||
Unusual Expense (Income) | |||||||
NOPBT | |||||||
NOPBT Margin | |||||||
Operating Taxes | |||||||
Tax Rate | |||||||
NOPAT | |||||||
Net income | |||||||
Dividends | |||||||
Dividend yield | |||||||
Proceeds from repurchase of equity | |||||||
BB yield | |||||||
| Debt | |||||||
Debt current | |||||||
Long-term debt | |||||||
Deferred revenue | |||||||
Other long-term liabilities | |||||||
Net debt | |||||||
| Cash flow | |||||||
Cash from operating activities | |||||||
CAPEX | |||||||
Cash from investing activities | |||||||
Cash from financing activities | |||||||
FCF | |||||||
| Balance | |||||||
Cash | |||||||
Long term investments | |||||||
Excess cash | |||||||
Stockholders' equity | |||||||
Invested Capital | |||||||
ROIC | |||||||
ROCE | |||||||
| EV | |||||||
Common stock shares outstanding | |||||||
Price | |||||||
Market cap | |||||||
EV | |||||||
EBITDA | |||||||
EV/EBITDA | |||||||
Interest | |||||||
Interest/NOPBT | |||||||